Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S47445 as adjunctive treatment for Major Depressive Disorder
NCT02805439Phase 2Completed
- Sponsor
- Servier
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of tulrampator in major depressive disorder (MDD), sponsored by Servier. Started Mar 2016; status: completed.
02
Drugs
tulrampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02805439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805439.